Drug-Induced Liver Injury (DILI) / Drug-Induced Hepatitis

1. Classification and Mechanisms

A. Direct / Intrinsic Hepatotoxicity

• Caused by the parent drug or, more commonly, a toxic reactive metabolite
• Dose-dependent - virtually every user will develop toxicity at a high enough dose
• Short latency (hours to days)
• Prototype: Acetaminophen (paracetamol)

B. Idiosyncratic Hepatotoxicity

C. Indirect Toxicity (Goldman-Cecil, p. 1587)

• Liver injury is a side effect of the drug's intended actions
• Examples: immunosuppressants that reactivate viral hepatitis (HBV, HCV); immune checkpoint inhibitors (pembrolizumab, nivolumab) that trigger T-cell-mediated hepatitis

2. Pathophysiology

Mechanisms of drug-induced liver injury - Harrison's Principles of Internal Medicine 22e

3. Clinical Presentations

Hepatocellular Pattern

• Resembles acute viral hepatitis: jaundice, nausea, RUQ pain, malaise
• Elevated ALT/AST (can exceed 10,000 IU/L in acetaminophen toxicity)
• Acetaminophen: characteristic very high aminotransferases with disproportionately low bilirubin - a biochemical signature of hyperacute injury

Cholestatic Pattern

• Pruritus, jaundice, elevated alkaline phosphatase
• Examples: estrogens, anabolic steroids, amoxicillin-clavulanate, chlorpromazine

Mixed Pattern

• Combination of both

Pattern Classification - The R-Value (Goldman-Cecil, p. 1588):

• R = (ALT ÷ ULN) ÷ (ALP ÷ ULN)
  • R ≥ 5: hepatocellular
  • R ≤ 2: cholestatic
  • 2 < R < 5: mixed

Granulomatous Hepatitis

Chronic Hepatitis

Acute Liver Failure (ALF)

• Most severe outcome - encephalopathy + coagulopathy
• DILI is the most common identifiable cause of ALF in Western countries

4. Diagnosis

International Consensus Criteria (Goldman-Cecil, Table 136-1)

1. ALT ≥ 5× ULN
2. ALP ≥ 2× ULN (in absence of bone pathology)
3. ALT ≥ 3× ULN AND total bilirubin ≥ 2× ULN (in absence of hemolysis/Gilbert's)

Hy's Law

Causality Assessment

• Detailed medication history: all prescription drugs, OTC medications, herbal/dietary supplements (including duration, dose, and timeline)
• Temporal relationship: onset of liver abnormalities after drug exposure and resolution after stopping (dechallenge)
• Rechallenge (generally avoided for safety): recurrence of injury confirms causality
• Exclusion of alternative diagnoses: viral hepatitis A/B/C/E, autoimmune hepatitis, ischemic hepatitis, biliary obstruction, Wilson disease
• RUCAM (Roussel Uclaf Causality Assessment Method): the most widely used structured scoring tool

Features Supporting Diagnosis

• Fever, rash, eosinophilia (suggest immunoallergic mechanism)
• Known association between the implicated drug and hepatotoxicity
• Time from exposure to onset fitting known patterns for that drug
• Improvement in liver tests within weeks of drug cessation (for hepatocellular DILI; cholestatic DILI may normalize more slowly)

Key Investigations

• LFTs (ALT, AST, ALP, GGT, bilirubin, albumin, PT/INR)
• Full blood count (eosinophilia)
• Viral serology: HBsAg, anti-HBc, anti-HAV IgM, anti-HCV, anti-HEV IgM
• Autoimmune markers: ANA, ASMA, LKM-1, IgG
• Abdominal ultrasound (exclude biliary obstruction, chronic liver disease)
• Liver biopsy: not routinely required but useful when diagnosis is uncertain, when autoimmune hepatitis cannot be excluded, or when DILI severity/histology will guide management

5. Important Causative Drugs

6. Management

A. Acetaminophen Hepatotoxicity (Direct Toxin)

• N-acetylcysteine (NAC) is the specific antidote - effective if given within 12 hours of ingestion, but still used even after injury has evolved
• NAC replenishes glutathione stores and prevents further NAPQI-mediated hepatocyte damage
• Activated charcoal if presentation within 1-2 hours of ingestion
• Serum acetaminophen levels: levels >300 μg/L at 4 hours post-ingestion predict severe damage; levels <150 μg/L suggest injury is highly unlikely
• Monitor PT/INR, creatinine, glucose, acid-base status
• Contact liver transplant center early if ALF develops

B. Idiosyncratic DILI - General Principles

1. Stop the offending drug immediately - this is the cornerstone of management
2. Supportive care: adequate nutrition, avoidance of further hepatotoxins, alcohol abstinence
3. Monitor LFTs until normalization (may take weeks to months for cholestatic DILI)
4. Do not rechallenge in most cases - risk of more severe recurrence

C. Specific Situations

• May be considered for immunoallergic DILI (especially if features of autoimmune hepatitis overlap), but evidence is limited and they are not routinely recommended
• Often used for checkpoint inhibitor-mediated hepatitis (Grade 2-4)

• Grade 1 (ALT <3× ULN): continue immunotherapy with monitoring
• Grade 2 (ALT 3-5× ULN): hold immunotherapy, consider corticosteroids (prednisolone 0.5-1 mg/kg/day)
• Grade 3-4 (ALT >5× ULN): permanently discontinue; high-dose IV methylprednisolone 1-2 mg/kg/day; add mycophenolate mofetil if refractory

• If clinical hepatitis develops (symptomatic or ALT >3× ULN), stop all anti-TB drugs
• Re-introduce one at a time after recovery, with monitoring

• Idiosyncratic, most severe in children under 2 years on polypharmacy
• Stop valproate; carnitine supplementation may be beneficial

D. Acute Liver Failure

• Transfer to a liver transplant center
• King's College Criteria or MELD score guide transplant listing
• Liver transplantation remains the definitive treatment for irreversible ALF from DILI

7. Prognosis

• Most cases resolve within weeks to months after drug withdrawal
• Hy's Law cases carry ~10% mortality without liver transplantation
• Cholestatic DILI generally has a better prognosis than hepatocellular DILI, but can persist for months ("prolonged cholestasis" or "vanishing bile duct syndrome" with some drugs, e.g., chlorpromazine, amoxicillin-clavulanate)
• Progression to chronic liver disease or cirrhosis is uncommon but possible

Recent Evidence (PubMed 2024-2026)

• A 2024 Chinese practice guideline (PMID 40198161) for primary care settings and a 2024 anti-TB drug DILI guideline (PMID 39497389) have been published, reflecting ongoing standardization of diagnostic criteria and management protocols.

• Harrison's Principles of Internal Medicine, 22nd ed. (2025), Ch. 351
• Goldman-Cecil Medicine, Ch. 136
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Ch. 88
• Morgan & Mikhail's Clinical Anesthesiology, 7th ed.

Nutrition and Weightlifting in Drug-Induced Hepatitis

PART 1: Recovery - Nutrition During DILI

General Principles

Energy Intake

• Avoid fasting - even short fasting worsens DILI by depleting hepatic glutathione, which is the liver's primary antioxidant defense against toxic drug metabolites (particularly critical for acetaminophen hepatotoxicity)
• Target 25-35 kcal/kg/day for most patients (higher end if malnourished or with significant liver injury)
• Small, frequent meals (5-6 per day) help maintain blood glucose and reduce hepatic metabolic load
• Eat a protein-containing snack before bed to reduce overnight fasting; limit overnight fast to under 7 hours

Protein

• Do not restrict protein in acute DILI (unlike historically recommended for encephalopathy) unless overt hepatic encephalopathy is present
• Target 1.2-1.5 g/kg/day of high-quality protein - this supports liver cell regeneration
• Good sources: eggs, poultry, fish, dairy (milk, yoghurt), legumes
• If encephalopathy develops: short-term modest protein restriction may be needed, then resume adequate intake as encephalopathy resolves; branched-chain amino acids (BCAAs) may be considered as an alternative protein source

Carbohydrates

• Adequate carbohydrate intake maintains hepatic glycogen and spares protein from being used for energy
• Prioritize complex carbohydrates: oats, rice, sweet potato, whole grains
• Avoid alcohol entirely - alcohol induces CYP2E1 and depletes glutathione, directly potentiating hepatotoxicity

Fats

• Avoid high-fat meals acutely, which increase hepatic metabolic burden
• Avoid saturated and trans fats
• Small amounts of healthy fats (olive oil, oily fish) are acceptable
• Avoid vitamin A megadosing - high-dose vitamin A is directly hepatotoxic and worsens liver disease (Harrison's)

Key Micronutrients

• N-acetylcysteine (NAC) - the most evidence-based intervention; replenishes glutathione. Used medically for acetaminophen overdose but also given to support general recovery in severe DILI
• Zinc - commonly deficient in liver disease; supports immune function and wound healing
• B vitamins (B1/thiamine, B6, B12, folate) - often depleted in liver disease
• Avoid high-dose iron supplements - iron accumulates in damaged hepatocytes and worsens oxidative injury
• Avoid copper supplements - can be hepatotoxic in excess when liver is already injured

Hydration

• Maintain good hydration to support renal clearance of drug metabolites
• Avoid anything that stresses the kidneys (NSAIDs, excess caffeine) since acetaminophen DILI can cause concurrent renal injury

What to Avoid

PART 2: Weightlifting and Exercise During Recovery

Acute Phase (Active Liver Injury - Elevated ALT/AST, Jaundice)

• Rest from strenuous exercise - heavy resistance training significantly raises ALT and AST from muscle breakdown, which confounds liver monitoring and increases overall metabolic burden on the liver
• The EASL DILI guidelines explicitly note that "aminotransferase elevations are often confounded by the effects of physical exercise" during recovery - making it harder to track liver healing
• Light walking is acceptable and may improve circulation and mood
• Resume weightlifting only after LFTs normalize or are trending strongly downward, typically confirmed by your physician

Recovery Phase (Improving LFTs, Asymptomatic)

• Gradually reintroduce activity: walking → light aerobic exercise → bodyweight training → progressive resistance training
• Diet and exercise together have been shown to reverse liver inflammation and reduce fibrosis (University of Missouri study, 2023)
• Avoid training to exhaustion - this generates reactive oxygen species that further challenge a recovering liver

Chronic/Stable Phase (LFTs Normal)

• Full return to training is appropriate
• Regular moderate-to-vigorous exercise is actually hepatoprotective - improves insulin sensitivity, reduces hepatic fat, and reduces inflammatory cytokines
• Resistance training specifically reduces visceral fat and improves liver enzyme profiles

PART 3: Prevention - Supplements and Substances Weightlifters Must Avoid

High-Risk Supplements Commonly Used by Weightlifters

Safe Supplementation After Recovery

• Protein supplements (plain whey, casein, pea protein): Generally safe; choose third-party certified products (NSF Certified for Sport, Informed Sport)
• Creatine monohydrate: Well-established safety profile; acceptable
• Vitamin D (moderate dose, not megadose): Often deficient; appropriate supplementation is safe
• Omega-3 fatty acids: Anti-inflammatory; no hepatotoxicity at standard doses
• Magnesium, zinc: Safe at standard doses; support muscle recovery
• Avoid ALL proprietary "fat burner," "pre-workout," or "test booster" blends - these frequently contain undisclosed hepatotoxic compounds or are contaminated (PMID 38826497 - 2024 case series on cholestasis from contaminated bodybuilding supplements)

Label Reading Rules for Athletes

• Products with long lists of proprietary blends = higher risk
• "Natural" or "herbal" does not mean safe for the liver
• Any product with a disclaimer like "not for individuals with liver disease" is a red flag
• Always check LiverTox - the NIH's free database of hepatotoxic drugs and supplements

Summary Table: Return to Training Timeline

UDCA (Ursodeoxycholic Acid) for Drug-Induced Hepatitis

The Core Position: Empirical Use, Weak Evidence

What the Major Guidelines Say

Mechanisms - Why UDCA Could Help

Clinical Evidence - What the Case Series Show

• Improvements seen in both cholestatic/mixed and hepatocellular DILI patterns (no statistically significant difference between groups)
• Most commonly benefited drugs: amoxicillin-clavulanate, flucloxacillin, bosentan, anabolic steroids
• Clinical and laboratory improvement typically occurred within 7-12 weeks of UDCA treatment initiation
• UDCA doses used ranged from 15 to 45 mg/kg/day; no clear dose-response relationship observed
• Maximum reported dose: 1,500 mg/day with no adverse effects
• Beneficial responses also reported in immune checkpoint inhibitor hepatitis refractory to steroids (used as add-on to corticosteroids)
• Preventive role: some evidence UDCA reduces the incidence of DILI when co-prescribed with known hepatotoxic drugs (e.g., methotrexate, anti-TB regimens)

Practical Use - When to Consider UDCA

• Cholestatic or mixed DILI - particularly with jaundice, pruritus, and elevated ALP/GGT
• Prolonged cholestasis / vanishing bile duct syndrome - where bile duct injury may persist despite drug withdrawal (associated with drugs like chlorpromazine, amoxicillin-clavulanate)
• Anabolic steroid-induced cholestasis - one of the better-documented scenarios

• Cholestatic DILI from anti-TB drugs (UDCA included in Chinese 2024 TB-DILI guidelines)
• Checkpoint inhibitor hepatitis not responding to steroids alone (combined with corticosteroids)
• Symptom control of pruritus in cholestatic DILI (AASLD 2023)

• Pruritus from cholestasis: UDCA 300 mg twice daily is a reasonable first step before adding cholestyramine or rifampicin

Dose

• Standard range in DILI case reports: 10-15 mg/kg/day in 2-3 divided doses (similar to PBC dosing)
• Some cases used up to 45 mg/kg/day without toxicity, though the optimal dose for DILI is not established
• Duration: typically continued until LFTs normalize or plateau, often 2-4 months

Safety

• Loose stools / mild diarrhea (usually dose-dependent)
• Rarely: pruritus worsening at very high doses in complete biliary obstruction (contraindication)

Summary

• Teschke R. Treatment of Drug-Induced Liver Injury. Biomedicines 2022 (PMID 36672522)
• Bessone F et al. UDCA for Drug-Induced Liver Disease. Seminars in Liver Disease 2024
• EASL DILI Clinical Practice Guidelines 2019
• AASLD Practice Guidance on DILI 2023
• PMC11797819 - UDCA mechanisms and clinical evidence 2025

Ursodeoxycholic Acid (UDCA / Ursodiol) - Uses and Mechanism of Action

1. Chemistry and Origin

Major bile acid structures - Goodman & Gilman's Pharmacological Basis of Therapeutics

2. Mechanisms of Action

A. Replacement of Toxic Hydrophobic Bile Acids

B. Choleretic / Bile Flow Stimulation

• Upregulating expression of bile acid transporters, particularly BSEP (bile salt export pump) and MRP2 on the canalicular membrane
• Stimulating vesicular exocytosis at the canalicular level
• Increasing bicarbonate-rich cholangiocyte secretion ("bicarbonate umbrella"), which protects the bile duct epithelium from protonated toxic bile acids

C. Cytoprotection of Hepatocytes

• Anti-apoptotic: stabilizes the mitochondrial membrane, preventing cytochrome c release and caspase activation; inhibits the Fas/FasL apoptotic pathway
• Anti-necrotic: reduces toxic bile acid-induced membrane disruption and calcium overload
• Mitochondrial protection: preserves mitochondrial membrane potential and β-oxidation capacity

D. Immunomodulation

• Reduces aberrant MHC class I and II expression on hepatocytes and cholangiocytes (which drives immune-mediated destruction)
• Reduces circulating IgM and IgG levels in PBC
• Modulates T-lymphocyte and NK cell activity
• Downregulates pro-inflammatory cytokines (Robbins Basic Pathology, p. 2251)

E. Reduction of Cholesterol Saturation / Litholytic Action

• Decreases biliary cholesterol secretion by suppressing hepatic HMG-CoA reductase and cholesterol 7α-hydroxylase
• Reduces cholesterol absorption from the gut
• Makes bile less lithogenic (less saturated with cholesterol)
• Directly dissolves cholesterol crystals in gallstones over time

F. Antioxidant Effects

• Scavenges reactive oxygen species (ROS) generated during drug metabolism (CYP450 reactions)
• Reduces oxidative stress in hepatocytes subjected to toxic metabolites

G. Endoplasmic Reticulum (ER) Stress Relief

• Attenuates ER stress triggered by accumulation of toxic metabolites and misfolded proteins in hepatocytes

3. Pharmacokinetics (ADME)

• Absorption: well absorbed orally via passive and active transport in the small intestine; undergoes extensive first-pass extraction by the liver
• Distribution: becomes a major biliary and plasma bile acid after repeated dosing; enters enterohepatic circulation
• Metabolism: conjugated with glycine and taurine in the liver before biliary secretion; largely reabsorbed in the terminal ileum (>95% enterohepatic recycling)
• Elimination: primarily fecal excretion
• Taking UDCA with food improves absorption and enterohepatic cycling

4. Clinical Uses and Doses

5. Second-Line Options When UDCA Fails

• Obeticholic acid (OCA) - a potent farnesoid X receptor (FXR) agonist; approved as second-line add-on or monotherapy in UDCA-intolerant patients. Mechanism: suppresses hepatic bile acid synthesis via FXR → reduced bile acid pool size; increases canalicular bile acid excretion. Dose: 5-10 mg once daily. Important: black box warning for hepatic decompensation in incorrectly dosed cirrhotic patients (dose must be reduced to 5 mg weekly in Child-Pugh B/C). Most common side effect: pruritus (Goodman & Gilman's, p. 1124)
• Fibrates (bezafibrate, fenofibrate) - PPARα agonists with anti-cholestatic effects; now recommended as second-line by some guidelines
• Budesonide - for PBC with overlap autoimmune features (non-cirrhotic only)

6. Adverse Effects

• Loose stools / mild diarrhea (most common, usually transient, dose-dependent)
• Nausea, headache, abdominal discomfort
• At high doses (>25-28 mg/kg/day in PSC): paradoxically worsens outcomes in PSC (increased risk of varices, transplantation, death in one RCT) - this is an important warning

• Complete biliary obstruction (mechanical)
• Acute cholangitis
• Calcified, pigment, or radio-opaque gallstones (UDCA cannot dissolve these)
• Allergy to bile acids

7. Summary: Where UDCA Stands

• Goodman & Gilman's Pharmacological Basis of Therapeutics, Ch. 54
• Goldman-Cecil Medicine, Ch. 110 (PSC)
• Robbins & Kumar Basic Pathology
• Teschke R. Treatment of DILI. Biomedicines 2022 (PMID 36672522)
• EASL DILI Clinical Practice Guidelines 2019